CBV Cannabivarin Cannabivarol CAS: 33745-21-0

CAS NO: 33745-21-0
CBV Cannabivarin Cannabivarol
Chemical Name: Cannabivarol
Molecular Formula: C19H22O2
Formula Weight: 282.38
CAS No.: 33745-21-0
Description Review
Description



CBV (Cannabisvarin Cannabivarol) is a substance of curiosity and scientific interest in the wide universe of cannabis chemicals. The purpose of this article is to investigate the chemical nature, possible advantages, and safety concerns of CBV.




Search Terms on Google "Properties of CBV Cannabivarin," "Exploring the pharmacology of Cannabivarol," "Research on CBV cannabinoids." "Exploring the medical applications of Cannabivarol,"


Highly competitive products
Similar in prominence to CBD or THC, CBV is a less well-known cannabinoid with fewer direct competitors. Some lesser cannabinoids, like CBC (Cannabigerol) or CBC (Cannabichromene), may be studied in the same way.


Benefits for Your Health
At this stage, the health advantages of CBV are somewhat conjectural, however they might have anti-inflammatory effects and neuroprotective qualities like other cannabinoids.


Possible Repercussions
It is necessary to do significant study in order to completely understand the impact that cannabidiol (CBD) has on the human body. This is especially true with respect to the way in which it interacts with the endocannabinoid system. There are numerous cannabinoids.


Product Design Mechanism
Cannabinoid receptors (CB1 and CB2) are likely targeted by CBV, similar to other cannabinoids. However, more research needs to be done to figure out how it works.


What are the risks and effects?
It is not known if CBV is safe to use. Some of the possible adverse effects of cannabinoids include dry mouth, dizziness, and changes in mood or appetite. Other cannabinoids may also have potential adverse effects.


Information on Dosing
There are no CBV dosage recommendations. It is important to proceed with caution and get medical advice before using anything.


Important considerations
Cautious behavior is advised for individuals who have specific medical conditions or are prescribed particular medications. We don't have enough information about safety to tell women who are pregnant or nursing not to use it.


In summary
An exciting new direction for cannabis research, CBV (Cannabivarin Cannabivarol) has medicinal possibilities that have not been thoroughly investigated. The trip that it will take from being a chemical that is not as well-known to being a potentially big participant in the cannabis area will be an interesting one to watch.

CBV Cannabivarin Cannabivarol CAS: 33745-21-0  
People Also ask

What is CBV Cannabivarin Cannabivarol's legal status?
A: The legal status of CBV varies by location and is often linked to the wider legal framework around cannabis. For precise details, it is imperative to refer to up-to-date local regulations.


Q: Can CBV be used to help certain health problems?
As of right now, there isn't enough evidence to back up the usage of CBV to treat certain medical issues. There is a possibility that further research may shed light on its medicinal potential.

Is there any information on CBV's interactions with medications?
A: The possible interactions between CBV and other drugs are not well known currently since there have not been enough extensive research conducted on CBV. Before using CBV in addition to other therapies, it is recommended to speak with medical authorities.

Top ten keywords from Google and Synonyms:

  1. Non-psychoactive cannabinoid
  2. Cannabis
  3. Health benefits
  4. Potential as an antimicrobial agent
  5. Anti-inflammatory properties
  6. Neuroprotective effects
  7. CB1 and CB2 receptors
  8. Cannabinoid research
  9. Legal status of CBV
  10. Anti-tumor effects
  11. "CBV Cannabivarin research,"
  12. "Cannabivarol chemical properties,"
  13. "Effects of CBV cannabinoid,"
  14. "CBV vs CBD comparison,"
  15. "Cannabinoid CBV therapeutic potential,"
  16. "Legal status of Cannabivarol,"
  17. "CBV Cannabivarin pharmacology,"
  18. "Safety profile of CBV,"
  19. "Cannabinoid receptors and CBV,"
  20. "Novel cannabinoids study."
  21.  

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code